AKT1 and prostate carcinoma: Indeed, the PI3K pathway is directly responsible for AKT activation and provides an intrinsic bypass mechanism able to enhance both the survival and proliferation of prostate cancer cells lacking AR signaling, making these cells resistant to androgen therapy [50].